

Transcript of Paul A. Bunn, Jr., M.D.

Date: July 11, 2017

Case: Apotex Inc., et al. -v- OSI Pharmaceuticals, Inc. (PTAB)

Planet Depos

Phone: 888.433.3767

Email:: transcripts@planetdepos.com

www.planetdepos.com



1	UNITED STATES PATENT AND TRADEMARK OFFICE							
2	BEFORE THE PATENT TRIAL AND APPEAL BOARD							
3	APOTEX INC., APOTEX CORP., APOTEX PHARMACEUTICALS							
4	HOLDINGS INC., and APOTEX HOLDINGS, INC.,							
5	Petitioners,							
6	V •							
7	OSI PHARMACEUTICALS, INC.,							
8	Patent Owner,							
9								
10								
11	U.S. Patent No. 6,900,221							
12	Case No: IPR2016-01284							
13	Case No. IPRZUIO-UIZO4							
14	DEPOSITION OF PAUL A. BUNN, JR., M.D July 11, 2017							
15								
16 17	PURSUANT TO NOTICE, the deposition of PAUL A. BUNN, JR., M.D. was taken on behalf of the							
18	Petitioners at 1225 17th Street, Suite 2600, Denver, Colorado, on July 11, 2017, at 8:01 a.m., before Wendy C. Heath, Certified Realtime Reporter, Registered							
19	Professional Reporter and Notary Public within Colorado.							
20								
21								
22								



1	APPEARANCES						
2	For the Petitioners:						
3	W. BLAKE COBLENTZ, ESQ.						
4	W. BLAKE COBLENTZ, ESQ. ERIC J. CHOI, ESQ. Cozen O'Connor PC 1200 Nineteenth Street Northwest						
5	Washington, D.C. 20036						
6 7	For the Patent Owner:						
8	EMILY R. WHELAN, ESQ. KEVIN M. YURKERWICH, ESQ. Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street						
9	Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109						
10	Doscon, Massachusects 02109						
11	Also Present:						
12	Andrea Tiglio, Ph.D.						
13							
14							
15							
16							
17							
18							
19							
20							
21							
22							



1									
1	INDEX								
2	EXAMINAT July 11,	PAGE							
3	By Mr. C	5							
4	INITIAL								
5	DEPOSITION EXHIBITS REFERENCE								
6	Exhibit	1030	Petitioners' Notice of Deposition of Paul A. Bunn, M.D., Under 37	9					
7			C.F.R., Section 42.53						
8	Exhibit	1031	Journal of Clinical Oncology	71					
9			article: Phase I and Pharmacologic Study of OSI-774, an Epidermal						
10			Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With						
11	Pubibi+	1022	Advanced Solid Malignancies	97					
12	EXHIDIC	1032	Journal of Clinical Oncology article: A Randomized, Phase II,	9 1					
13			Biomarker-Selected Study Comparing Erlontinib to Erlotinib						
14			Intercalated With Chemotherapy in First-Line Therapy for Advanced						
15	Pubibi+	1022	Non-Small-Cell Lung Cancer	101					
16	EXHIDIC	1033	Article: EGF receptor gene mutations are common in lung cancers from "never smokers" and	101					
17			are associated with sensitivity of						
18	Pubibi+	1 0 2 4	tumors to gefitinib and erlotinib	1 0 7					
19	EXHIDIC	1034	Article: This \$7,800-a-month cancer drug caused rashes and	107					
20			rarely worked. Now Trump could make FDA approvals even easier						
21	Exhibit	1035	Summary Minutes of Oncologic Drugs	117					
22			Advisory Committee, December 16, 2009						



1	DEPOSITION EXHIBITS: (Previously marked)								
2	Exhibit 1	001	Patent No: US 6,900,221 BI	42					
3	Exhibit 1		Provisional Application Cover Sheet and Provisional Application	12					
4 5	Exhibit 1	.009	Patent Number 5,747,498	54					
6	Exhibit 1		Article: Anticancer drug targets: Growth factors and growth factor signaling	87					
7	Exhibit 1		Article: Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of	90					
9			Epidermal Growth Factor Receptor Tyrosine Kinase						
10	Exhibit 2	021	Declaration of Dr. Paul Bunn	10					
12 13	Exhibit 2		American Society of Clinical Oncology Thirty-Fifth Annual Meeting, May 15-18, 1999, Atlanta, GA	76					
14 15	Exhibit 2		Review: Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer	67					
16									
17									
18									
20									
21									
22									

DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

